Status:
COMPLETED
Study Evaluating Isovorin in Advanced/Recurrent Gastric Cancer
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Gastric Cancer
Eligibility:
All Genders
20-77 years
Phase:
PHASE3
Brief Summary
The purpose of the study is to verify non-inferiority of survival time between Isovorin/5-fluorouracil (1-LV/5FU) therapy and TS-1 therapy in patients with inoperable advanced or recurrent gastric can...
Eligibility Criteria
Inclusion
- Gastric cancer diagnosed histologically or cytologically
- Normal organ function of bone marrow, heart, liver and kidney
- Age of 20-77
- Other inclusion applies
Exclusion
- Serious infection, heart disease, complication or organ disorder
- Ongoing administration of flucytosine
- Pregnant or breastfeeding women
- Other exclusion applies
Key Trial Info
Start Date :
May 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2008
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00195572
Start Date
May 1 2002
End Date
August 1 2008
Last Update
August 13 2009
Active Locations (43)
Enter a location and click search to find clinical trials sorted by distance.
1
Adachi-ku, Tokyo, Japan, 123-0855
2
Anjo, Japan, 446-8602
3
Aomori, Japan, 030-8553
4
Chiba, Japan, 260-8607